Vaccination with peptide of MHC class II molecules for treatment

Details Vaccination with peptide of MHC class II molecules for treatment Vaccination with peptide of MHC class II molecules for treatment

1995-06-07

2000-04-04

Cunningham, Thomas M.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

4241841, 530300, 530395, A61K 3900, C07K 1474

Patent

active

060457961

ABSTRACT:
The present invention provides immunogenic oligopeptides derived from the Major Histocompatibility Complex (MHC) glycoprotein protein sequences for use in compositions and methods for the treatment, prevention and diagnosis of deleterious immune responses, such as autoimmunity and allergies. The peptides are capable of inducing an immune response against glycoproteins encoded MHC alleles associated with the target disease. In preferred embodiments the peptides of the invention are derived from hypervariable region of the .beta. chain of an MHC Class II molecule associated with the deleterious immune response.

REFERENCES:
patent: 5130297 (1992-07-01), Sharma
patent: 5194425 (1993-03-01), Sharma
Acha-Orbea, H. et al., "T cell receptors in murine autoimmune disease"Ann Rev. Immunol.7:371-405 (1989).
Adorini, L. et al., "In vivocompetition between self peptides and foreign antigens in T-cell activation"Nature334:623-625 (1988).
Agrawal, B. et al., "T Cells That Recognize Peptide Sequences of Self MHC Class II Molecules Exist in Syngenic Mice"J. Immunol. 147 (2) :383-390 ( 1991).
Aharoni, R. et al., "Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-la complex"Nature351:147-150 (1991).
Anderson, D.C. et al., "A Mycobacterium leprai-Specific Human T Cell Epitope Cross-Reactive with an HLA-DR2 Peptide"Science242:259-261 (1998).
Benichuo, G et al., "Immunogenicity and Tolerogenicity of Self-Major Histocampatibility Complex Peptides"J. Exp. Med. 172:1341-1346 (1990).
Blasczyk, R. et al., "Soluble CD4, CD8, and HLA molecules in commerical immunoglobulin preparations"The Lancet341:798-790 (1993).
Bright, J.J. et al., "Vaccination with peptides from MHC class II beta chain hypervariable region causes allete-specific suppression of EAE"J. Neuroimmunol.67:119-124 (1996).
Brown, J.H. et al., "Three-dimesional struture of the human class II histocampatibility antigen HIA-DR1"Nature364:33-39 (1993).
Cohran, R.S. et al., eds., Robbin'Pathological Basis of Disease, 4th ed., Chapter 5, pp. 163-236 (1989).
German, R.N., Fundamental Immunology, 3rd edition, (W.E. Paul, ed.) Chapter 17, "The major Histocompatibility Complex"pp. 629-676 (1993).
Goodman, J.W., "Immunogenicity & Antigenic Specificity"in: Fundamental Immunology, pp. 101-108 (1991).
Gorga, J.C., "Structural Analysis of Class II Major histocompatibility Complex Proteins"Crit. Rev. Immunol. 11 (5) :305-335 (1992)T.
Hansen, T.H. et al., Fundamental Immunology, 3rd edition, (W.E. Paul, ed.) Chapter 16, "The Major Histocompatibility Complex"pp. 577-628 (1993).
Howell, M.D. et al., "Vaccination against experimental allergic encephalomyelitis with T-cell receptor peptides"Science246:668-670 (1989).
Kwak, L.W. et al., "Induction of Immune Responses in Patients With B-Cell Lymphomas, The Surface-Immunoglobulin Idiotype Expressed By Their Tumors", New Engl. J. Med. 327(17) :1209-1215 (1992).
Lamont, A.G. et al., "Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IA.sup.s molecules"Science246:2527-2531 (1992).
Li, H.F. et al., "Modulation of restricted class II T-cell responses by peptides derived from self class II molecule"Eur. J. Immunol. 22:2527-2531 (1992).
Margulise, D.H. et al., "Engineering Soluble Major Histocompatibilty Molecules: Why and How"Immunol. Res. 6: 101-116 (1987).
Mazerolles, F. et al., "Immunosuppressive Properties of Synthetic Peptides Derived from CD4 and HLA-DR Antigens"Cell55:497-504 (1988).
Moretta, A. et al., "Involvement of T44 Molecules in an Antigen-Independent Pathway of T Cell Activation"J. Exp. Med. 162:823-838 (1985).
Muller, S. et al., "Selective in vivo Inhibition of T-cell Activation by Class II MHC-Binding Peptides Administered in Soluble Form"J. Immunol. 145(12) :4006-4011 (1990).
Nicolle, M.W. et al., "Specific tolerence to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble MHC class II-peptide complexes"J. Clin. Invest. 93:1361-1369 (1994).
Parham, P., "Peptide feeding and cellular cookery"Nature30:793-795 (1990).
Ploegh, H. et al., "MHC class II dimer of dimers"Nature364:16-17 (1993).
Roudier, J. et al., "Tolerance to self peptide from the third hypervariable region of the E.sup.s chain. Implications for molecular mimicry models of autoimmune disease"Eur. J. Immunol. 21:2063-206 (1991).
Roudier, J. et al., "Immune response to peptides from the third hypervariable region of the .beta. chain of MHC class II molecules. Implications for the immune response to foreign antigens"Cancer Biol. 2:283-285 (1991).
Saskia, H. et al., "T Cells Sensitized To Synthetic HLA-DR3 Peptide Give Evidence of Continouos Presentation of Denatured HLA-DR3 Molecules by HLA-DP"J. Exp. Med. 169:1191-1196 (1989).
Schneck, J. et al., "Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: Estimation of the affinity of a T cell receptor for MHC"Cell56:47-55 (1989).
Schwartz, R.S., Fundamental Immunology, 3rd edition (W.F. Paul, ed.), Chapter 30 "Autoimmunity and Autoimmune Disease"pp. 1033-1095 (1993).
Sharma, S. et al., "Antigen-specific therapy of experimental allergic encephalomyelitis by solube class II Major histocompatibility complex-peptide complexes"Proc. Natl. Acad. Sci. USA88:11465-11469 (1991).
Sigal, N.H. et al., Fundamental Immunology , 3rd edition, (W.E. Paul, ed.) Chapter 25, "Immunosuppression"pp. 903-915 (1993).
Sriram, S. and Steinman, L., "Anti I-A antibody suppresses active encephalomyelitis: Treatment model for diseases linked to IR genes"J. Exp. Med158:1362-1367.
Steinman, L. et al., "In vivo effects of antibodies to immune response gene products: Prevention of expermental allergic encephalitis"Proc. Natl. Acad. Sci. USA78(11):7111-7114 (1981).
Steinman, L. "The Development of Rational Strategies for Selective Immunotherapy against Autoimmune Demyelinating Disease"Adv. Immunol. 49:357-379 (1991).
Topham, D.J. et al. "A sythetic peptide from the third hypervariable region of MHC class II .beta.chain as a vaccine for treatment of experimental allergic encephalomyelitis"Proc. Natl. Acad. Sci. USA 91-8005-8009 (1994).
Vandenbark, A.A. et al., "Immunization with a synethia T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis"Nature341:541-544.
Vladutiu, A.O. and Steinman, L., "Inhibition of experimental autoimmune thyroiditis in mice by anti-I-A antibodies"Cell Immunol. 109:169-180.
Waldor, M.K. et al., "In vivotherapy with monoclonal anti-I-A-antibody suppresses immune respones to acetylcholine receptor"Proc. Natl. Acad. Sci. USA. 80:2713-2717 (1983).
Winkelhake, J.L. et al., "Therapeutic Peptide Vaccines: Targeting the Antigen-recognition Unit in Autoimmune Diseases"Vaccine Res. 5(3) :119-135 (1996).
Wooley, P.H. et al., "Type II collgen-induced arthritis in mice: Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera"J. Immunol. 134 (4):2366-2374 (1995).
Wraith, D.C. et al/. "T cell recognition as the target for immune intervention in autoimmune disease"Cell57:709-715 (1989).
Zaller, D.M. et al., "Prevention and treatment of murine experimental allergic encephalomyelitis with T cell receptor V.beta.-specific antibodies"J. Exp. Med. 171:1943-1955 (1990).
Nancy E. Adelman et al. "TREATMENT OF (NZB X NZW) F .sup.1 DISEASE WITH ANTI-I-A MONOCLONAL ANTIBODIES", Brief Definitive Report, 158:1350-1355 (1983).
C. Boitard et al., "PREVENTION OF DIABETES IN NONOBESE DIABETIC MICE BY ANTI-I-A MONOCLONAL ANTIBODIES: TRANSFER OF PROTECTION BY SPLENIC T CELLS", Proc, Natl. Acad. Sci. USA. 85:9719-9723 (1988).
J. Lee Nelson et al., "MATERNAL-FETAL DISPARITY IN HLA CLASS II ALLOANTIGENS AND THE PREGNANCY-INDUCED AMELIORATION OF RHEUMATOID ARTHRITIS", The New England Journal of Medicine pp. 466-471 (Aug. 12, 1993).
Sophie Salvat et al., "TOLERANCE TO A SELF-PEPTIDE FROM THE THIRD HYPERVARIABLE REGION OF HLA DRB1 0401 IN RHEUMATOID ARTHRITIS PATIENTS AND NORMAL SUBJECTS", The American Association of Immunologists pp. 5321-5329 (1994).
Roudier, J., et al. (1991) "Tolerance to self pep

Affiliated with

Also associated with

Rating

Vaccination with peptide of MHC class II molecules for treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccination with peptide of MHC class II molecules for treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccination with peptide of MHC class II molecules for treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-362264